Mitsui Toatsu Chemicals, Incorporated

Mitsui Chemicals, Inc.

Shiro Takagi

Kazuya Sakai

Tamotsu Fukuda

Yasuyuki Kuroiwa

Yukio Shimazaki

Hisayoshi Ooka

Junya Fujiwara

Fumiki Shimada

Ayako Watanabe

Yoshio Shiga

Noboru Satozawa

Kenji Kibayashi

Izumi Mita

Tomoko Yokomatsu

Pyrazoline derivative or tetrahydropyridazine derivative and medicinal use thereof

A freeze-dried monoclonal antibody preparation is prepared by adding to a solution of the monoclonal antibody gelatin or carboxylic acid or its salt, to prevent denaturation of the monoclonal antibodies during freeze-drying. Freeze-dried monoclonal antibody preparations having stablized antigen-binding activity result and may be used as an adminiculum for immunoauxotherapy for prophylaxis and treatment of bacterial infectious diseases and viral infectious diseases.

Freeze-dried preparation containing monoclonal antibody

The present invention provides an anti-VEGF human monoclonal antibody capable of binding to human VEGF to neutralize its activity, a cell strain producing said human monoclonal antibody, and a vascularization inhibitor containing said human monoclonal antibody. Hybridoma strains VA01 and BL2 producing the anti-VEGF human monoclonal antibody can also be provided according to the present invention by transformation with Epstein-Barr Virus (EBV) of human lymphocyte producing anti-human VEGF antibody and then fusing the transformant cells with human myeloma cells. The monoclonal antibody of the present invention can serve as a vascularization inhibitor which is useful for human because it is derived from human and capable of binding specifically to VEGF participating in vascularization, to inhibit the migration or proliferation of vascular endothelial cells.

Anti-VEGF human monoclonal antibody

Growing community of inventors

Mobara, Japan

Shiro Takagi